Related items

As Ukraine advances on its path toward EU accession, the country will need legal experts who understand both Ukrainian law and the EU’s complex legal framework. Jones Day is helping prepare the next generation of lawyers through its ‘Future in Europe Program – European Union Law Studies for Ukraine’, launched in April 2026 in partnership with Chernivtsi National University. Open to law students across Ukraine, the 14-session online course covers core areas of EU law, from internal market legislation and trade to competition, intellectual property, human rights and environmental, social and governance considerations. By expanding access to legal education, the programme supports Ukraine’s future in the EU and strengthens the foundations for the rule of law. Read the full story on Invested in Europe. 

Intel has called Ireland home since 1989, investing more than €30 billion and supporting 4,900 jobs. Alongside this long-term commitment, the company is helping strengthen local communities through its Signature Charity initiative. For the past 16 years, the Intel Foundation and Intel employees have selected a charity each year to support through volunteering and fundraising. In 2025, Intel Ireland chose Teach Tearmainn, the only organisation in County Kildare dedicated to supporting women and children experiencing domestic violence and abuse. Through fun runs, cycling events, a triathlon, a giving campaign, employee-led fundraising and recycling initiatives, Intel employees raised €80,000 for the charity – the company’s largest charity donation to date. These efforts show how long-term investment, employee engagement and community partnerships can help deliver meaningful support where it is needed most. Read the full story on Invested in Europe.

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation. 

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment. 

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.